Sharon T. Sullivan

1.0k total citations
25 papers, 300 citations indexed

About

Sharon T. Sullivan is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Sharon T. Sullivan has authored 25 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 11 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Sharon T. Sullivan's work include Multiple Myeloma Research and Treatments (14 papers), Protein Degradation and Inhibitors (9 papers) and HIV/AIDS drug development and treatment (6 papers). Sharon T. Sullivan is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Protein Degradation and Inhibitors (9 papers) and HIV/AIDS drug development and treatment (6 papers). Sharon T. Sullivan collaborates with scholars based in United States, France and Spain. Sharon T. Sullivan's co-authors include Clyde E. Hart, Lynn Paxton, Artur Ramos, Lisa A. Grohskopf, Shambavi Subbarao, Timothy J. Bush, Charlene S. Dezzutti, Tammy Evans‐Strickfaden, Jeffrey L. Lennox and Alexander M. Lesokhin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Virology.

In The Last Decade

Sharon T. Sullivan

21 papers receiving 295 citations

Peers

Sharon T. Sullivan
Comparison fields: 5 of 50
  • Oncology 99
  • Virology 88
  • Infectious Diseases 79
  • Microbiology 71
  • Hematology 66
Replace Dionne Cain with:
Dionne Cain United Kingdom
Sandeep Narpala United States
Sary El Daker Italy
George Krashias Cyprus
Esther D. Quakkelaar Netherlands
Tom Cole United Kingdom
Shariq Mujib Canada
Claudia Goulston United States
Jean Paul Lévy France
Brigitte Müllauer Austria
Dionne Cain United Kingdom View profile →
Citations per field, relative to Sharon T. Sullivan
Sharon T. Sullivan · 1×
Citations per year, relative to Sharon T. Sullivan
Sharon T. Sullivan · 1×

Countries citing papers authored by Sharon T. Sullivan

Since Specialization
Citations

This map shows the geographic impact of Sharon T. Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon T. Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon T. Sullivan more than expected).

Fields of papers citing papers by Sharon T. Sullivan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon T. Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon T. Sullivan. The network helps show where Sharon T. Sullivan may publish in the future.

Co-authorship network of co-authors of Sharon T. Sullivan

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon T. Sullivan. A scholar is included among the top collaborators of Sharon T. Sullivan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon T. Sullivan. Sharon T. Sullivan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial
2025 ·Blood ·Cyrille Touzeau, Hanlon Sia, Sebastian Grosicki, Paz Ribas, (unknown), Paula Rodríguez‐Otero, Suzanne Trudel, Takashi Ikeda, Antonio Lazzaro, (unknown), Sharon T. Sullivan, Domenico Cieri, Eric Leip, Meletios Α. Dimopoulos
0
2
Elranatamab in Combination With Daratumumab and Lenalidomide (EDR) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant: Initial Results from MagnetisMM-6 Part 1
2025 ·Clinical Lymphoma Myeloma & Leukemia ·Suzanne Trudel, Hang Quach, Luděk Pour, Sebastian Grosicki, Hanlon Sia, Jiří Minařík, Ja Min Byun, Cyrille Touzeau, (unknown), Sharon T. Sullivan, Eric Leip, (unknown), Andrea Viqueira, Meletios Α. Dimopoulos
0
3
Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3
2025 ·Blood ·Alexander M. Lesokhin, Rubén Niesvizky, Bertrand Arnulf, (unknown), Christopher Strouse, Carlos Fernández de Larrea, David H. Vesole, Yuya Nagai, Sharon T. Sullivan, Eric Leip, Andrea Viqueira, Nizar J. Bahlis
0
4
Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma
2025 ·Targeted Oncology ·(unknown), (unknown), (unknown), Sharon T. Sullivan, Erik Vandendries, Athanasia Skoura, Diane Wang, Mohamed Elmeliegy
2
5
MM-1037: Elranatamab (ELRA) in Combination With Daratumumab and Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant: Initial Results From MagnetisMM-6 Part 1
2025 ·Clinical Lymphoma Myeloma & Leukemia ·Hang Quach, Luděk Pour, Sebastian Grosicki, Hanlon Sia, Jiří Minařík, Ja Min Byun, Cyrille Touzeau, (unknown), Sharon T. Sullivan, Eric Leip, (unknown), Andrea Viqueira, Meletios Α. Dimopoulos
0
6
Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1.
2025 ·Journal of Clinical Oncology ·Hang Quach, Luděk Pour, Sebastian Grosicki, Hanlon Sia, Jiří Minařík, Ja Min Byun, Cyrille Touzeau, (unknown), Sharon T. Sullivan, Eric Leip, (unknown), Andrea Viqueira, Meletios Α. Dimopoulos
2
7
MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
2024 ·Blood ·H. Miles Prince, Nizar J. Bahlis, Paula Rodríguez‐Otero, Lionel Karlin, Luke P. Akard, (unknown), Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin
5
8
Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
2024 ·HemaSphere ·Michael H. Tomasson, Shinsuke Iida, Rubén Niesvizky, Mohamad Mohty, Nizar J. Bahlis, Joaquín Martínez‐López, Guenther Koehne, Paula Rodríguez‐Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T. Sullivan, Alexander M. Lesokhin
23
9
P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
2023 ·HemaSphere ·Salomon Manier, Alexander M. Lesokhin, Mohamad Mohty, Rubén Niesvizky, Christopher Maisel, Bertrand Arnulf, Sarah M. Larson, (unknown), Xavier Leleu, Lionel Karlin, David H. Vesole, Nizar J. Bahlis, Carlos Fernández de Larrea, Noopur Raje, Eric Leip, Sharon T. Sullivan, Mohamed Elmeliegy, Andrea Viqueira, Ajay K. Nooka
3
10
S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3
2023 ·HemaSphere ·Mohamad Mohty, Michael H. Tomasson, Bertrand Arnulf, Nizar J. Bahlis, Paula Rodríguez‐Otero, Joaquín Martínez‐López, Cyrille Touzeau, Hang Quach, Julien Depaus, Hisayuki Yokoyama, Salomon Manier, Noopur Raje, Marc S. Raab, Emma Searle, Eric Leip, Sharon T. Sullivan, Akos Czibere, Andrea Viqueira, Alexander M. Lesokhin
4
11
Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
2022 ·Journal of Clinical Oncology ·Alexander M. Lesokhin, Bertrand Arnulf, Rubén Niesvizky, Mohamad Mohty, Nizar J. Bahlis, Michael H. Tomasson, Paula Rodríguez‐Otero, Hang Quach, Noopur Raje, Shinsuke Iida, Marc‐Steffen Raab, Akos Czibere, Sharon T. Sullivan, Eric Leip, Andrea Viqueira, Xavier Leleu
15
12
Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma
2021 ·Blood ·Alexander M. Lesokhin, Shinsuke Iida, Don A. Stevens, Afshin Eli Gabayan, (unknown), Sharon T. Sullivan, Marc‐Steffen Raab
7
13
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
2015 ·Leukemia & lymphoma ·Nina D. Wagner‐Johnston, André Goy, Maria Alma Rodriguez, W. Christopher Ehmann, Paul A. Hamlin, John Radford, Catherine Thiéblemont, Cheolwon Suh, John Sweetenham, Yifan Huang, Sharon T. Sullivan, Erik Vandendries, Christian Gisselbrecht
32
14
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).
2014 ·Journal of Clinical Oncology ·Nam H. Dang, Michinori Ogura, Sylvie Castaigné, Luis Fayad, Mats Jerkeman, John Radford, Antonio Pezzutto, Igor Bondarenko, Douglas A. Stewart, Michael Shnaidman, Sharon T. Sullivan, Erik Vandendries, Kensei Tobinai, (unknown), Paul A. Hamlin, Eva Giné, Kiyoshi Ando
14
15
Female Genital Tract Shedding of CXCR4-Tropic HIV Type 1 Is Associated with a Majority Population of CXCR4-Tropic HIV Type 1 in Blood and Declining CD4 + Cell Counts
2012 ·AIDS Research and Human Retroviruses ·Richard E. Haaland, Sharon T. Sullivan, Tammy Evans‐Strickfaden, Jeffrey L. Lennox, Clyde E. Hart
5
16
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy
2011 ·Blood ·Nina D. Wagner‐Johnston, André Goy, Maria Alma Rodriguez, (unknown), Paul A. Hamlin, John Radford, Catherine Thiéblemont, Cheolwon Suh, John Sweetenham, Ying Jiang, Sharon T. Sullivan, Erik Vandendries, Christian Gisselbrecht
3
17
Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women
2010 ·AIDS ·Colleen F. Kelley, Sharon T. Sullivan, Jeffrey L. Lennox, Tammy Evans‐Strickfaden, Clyde E. Hart
6
18
Population Pharmacokinetic Modeling of BeneFIX in Pediatric and Adult Patients with Hemophilia B Demonstrates Weight as An Important Factor Contributing to Inter-Patient PK Variability.
2008 ·Blood ·Chandrasekhar Udata, Sharon T. Sullivan, Patrick Kelly, David A. Roth, Meng Xu
7
19
Diversity, Divergence, and Evolution of Cell-Free Human Immunodeficiency Virus Type 1 in Vaginal Secretions and Blood of Chronically Infected Women: Associations with Immune Status
2005 ·Journal of Virology ·Sharon T. Sullivan, Usha Mandava, Tammy Evans‐Strickfaden, Jeffrey L. Lennox, Tedd V. Ellerbrock, Clyde E. Hart
27
20
In Vitro Comparison of Topical Microbicides for Prevention of Human Immunodeficiency Virus Type 1 Transmission
2004 ·Antimicrobial Agents and Chemotherapy ·Charlene S. Dezzutti, (unknown), Artur Ramos, Sharon T. Sullivan, (unknown), Timothy J. Bush, Lisa A. Grohskopf, Lynn Paxton, Shambavi Subbarao, Clyde E. Hart
114

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dionne Cain Breakdown of academic impact, for papers by Sandeep Narpala Breakdown of academic impact, for papers by Sary El Daker Breakdown of academic impact, for papers by George Krashias Breakdown of academic impact, for papers by Esther D. Quakkelaar Breakdown of academic impact, for papers by Tom Cole Breakdown of academic impact, for papers by Shariq Mujib Breakdown of academic impact, for papers by Claudia Goulston Breakdown of academic impact, for papers by Jean Paul Lévy Breakdown of academic impact, for papers by Brigitte Müllauer
Rankless by CCL
2026